Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: JF Quinnelly who wrote (1099)	8/9/1999 9:27:00 AM
From: LLCF	Read Replies (1) \| Respond to of 3202

Another deal expansion: <What will drive the stock> Well, here's some more molecules for the pipeline: Incyte Announces Bioinformatics Partnering Program and Expansion of Database Agreement With Rhone-Poulenc Rorer PALO ALTO, Calif., Aug. 9 /PRNewswire/ -- Incyte Pharmaceuticals, Inc. (Nasdaq: INCY - news) announced today that Rhone-Poulenc Rorer (NYSE: RP - news) has expanded its agreement with Incyte, which was originally signed in December of 1997. The expanded agreement will include access to the LifeSeq® Gold assembled database, the LifeArray(TM) expression analysis software, and a bioinformatics collaboration. In addition, Incyte could receive future milestone payments and royalties on sales of products developed with Incyte technology and database information. Financial terms were not disclosed. ''We are pleased to be broadening our relationship with Incyte,'' said Francois Meyer, Head of Research for Rhone-Poulenc Rorer, Inc. ''There is tremendous value in Incyte's products that complements our internal research and development efforts. We believe this combination provides us with significant competitive advantage.'' ''The need for genomic data management tools is growing exponentially with the amount of genomic data being generated,'' said Roy A. Whitfield, Chief Executive Officer of Incyte. ''We are pleased to be able to aid scientists at Rhone-Poulenc Rorer with their data management needs.'' Incyte will collaborate with scientists at Rhone-Poulenc to provide customized bioinformatics solutions, building upon Rhone-Poulenc's internal bioinformatics capabilities. In addition, Incyte's LifeArray(TM) enterprise-wide software enables the management of vast quantities of data resulting from large-scale gene expression analysis. The combination of the powerful information management software and Incyte's LifeSeq® Gold assembled database provides scientists with powerful tools to exploit the explosion of genomic information for drug discovery and development. Rhone-Poulenc Rorer is the global pharmaceutical subsidiary of Rhone-Poulenc, dedicated to improving human health. Rhone-Poulenc S.A. is a leading life sciences company, growing through innovations in human, plant and animal health and through its specialty chemicals subsidiary, Rhodia. With sales in 1998 of FF86.8 billion (US$14.8 billion; Euros 13.2 billion), the company employs 65,000 people in 160 countries worldwide. The RPR Internet web site is at rp-rorer.com. Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases, genomic data management software, microarray-based gene expression services, related reagents and services. These products and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's web site at www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 1999. Incyte disclaims any intent or obligation to update these forward-looking statements. SOURCE: Incyte Pharmaceuticals, Inc.